Purpose: The purpose of this study was to evaluate the effect of focal double‑frequency yttrium‑aluminum‑garnet (YAG) laser therapy in patients with central serous chorioretinopathy (CSCR) resistant to intravitreal bevacizumab (IVB) injections.
Methods: This is a retrospective analysis of 16 eyes of 16 patients with CSCR of >3 months duration who had been previously treated with multiple injections of bevacizumab (average 2.7) with no improvement in best‑corrected visual acuity (BCVA). All patients had been treated using multiple spots of focal double‑frequency YAG laser over areas of focal and diffuse leak. Spectral domain‑optical coherence tomography (SD‑OCT) was done a day before laser treatment and at 1, 3, and 6 months after. Fluorescein angiography was done for all patients to locate leakage site before laser treatment.
Results: Mean age of patients was 37.6 ± 3.9 years. The baseline BCVA was improved significantly (P < 0.001) from 0.39 ± 0.45 logarithm of the minimum angle of resolution (log MAR) to 0.11 ± 0.43, 0.10 ± 0.44, and 0.09 ± 0.45 (log MAR) at 1, 3, and 6 months posttreatment, respectively. The baseline OCT mean central macular thickness decreased significantly (P < 0.001) from 554 ± 45 μm to 285 ± 38 μm, 279 ± 34 μm, 275 ± 33 μm at 1, 3, and 6 months posttreatment, respectively.
Conclusion: Focal double‑frequency YAG laser therapy improved the BCVA and reduced neurosensory detachment in patients with CSCR resistant to IVB injections.
|
